Table 1 Patient characteristics of the training cohort and validation cohort

metastasis

no

96 (63.2%)

42 (62.7%)

1

yes

56 (36.8%)

25 (37.3%)

gender

female

37 (24.3%)

16 (23.9%)

1

male

115 (75.7%)

51 (76.1%)

age

< 55

89 (58.6%)

35 (52.2%)

0.471022503

≥ 55

63 (41.4%)

32 (47.8%)

PLR

< 260

134 (88.2%)

55 (82.1%)

0.322032508

≥ 260

18 (11.8%)

12 (17.9%)

NLR

< 3.8

107 (70.4%)

50 (74.6%)

0.632751819

≥ 3.8

45 (29.6%)

17 (25.4%)

LMR

< 5.5

129 (84.9%)

56 (83.6%)

0.968289603

≥ 5.5

23 (15.1%)

11 (16.4%)

SII

< 1185

113 (74.3%)

49 (73.1%)

0.983563436

≥ 1185

39 (25.7%)

18 (26.9%)

clinical classification

1–2

22 (14.5%)

10 (14.9%)

1

3–4

130 (85.5%)

57 (85.1%)

T classification

1–2

78 (51.3%)

30 (44.8%)

0.456065962

3–4

74 (48.7%)

37 (55.2%)

N classification

0, 1

89 (58.6%)

40 (61.5%)

0.681561

2, 3

63 (41.4%)

25 (38.5%)

EBv.DNA

< 400

120 (78.9%)

53 (79.1%)

1

≥ 400

32 (21.1%)

14 (20.9%)

BMI

< 28

131 (86.2%)

60 (89.6%)

0.63962412

≥ 28

21 (13.8%)

7 (10.4%)

BSA

< 1.5

11 (7.2%)

3 (4.5%)

0.558705859

≥ 1.5

141 (92.8%)

64 (95.5%)